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The protein S-100B is a biomarker increasingly used within neurosurgery and neurointen-
sive care. As a relatively sensitive, yet unspecific, indicator of CNS pathology, potential
sources of error must be clearly understood when interpreting serum S-100B levels. This
case report studied the course of a 46-year-old gentleman with a chronic subdural hemor-
rhage, serum S-100B levels of 22µg/l, and a history of malignant melanoma. Both intra-
and extra-cranial sources of S-100B are evaluated and imply an unclear contribution of sev-
eral sources to the total serum concentration. Potential sources of error when interpreting
serum concentrations of S-100B are discussed.
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INTRODUCTION
A 46-year old gentleman was admitted to hospital after having been
found unconscious in his home. Past medical history included
malignant melanoma that had been radically excised 9 years pre-
viously and the patient, after several controls, was believed to be
in remission. There was no record of excessive alcohol- or other
drug abuse.
On admission the patient presented with a Glasgow Coma
Score (GCS) of 3, a dilated left pupil, bilaterally brisk reflexes,
and positive Babinski sign. There were no signs of neck stiff-
ness, fever, petechiae, or trauma. S-100B was not acquired on
admission (Figure 1). A CT scan showed a left-sided chronic sub-
dural hemorrhage (SDH), resulting in a midline shift of 15 mm
(Figure 2).
Evacuation of the subdural hematoma was performed. Intra-
operatively, the pressure within the hematoma was noted to be
low. The brain parenchyma failed to resume its natural posi-
tion after the evacuation. The first S-100B sample was obtained
post-operatively 4 h and 22 min after the paramedics were alerted.
S-100B was elevated (1.9µg/l; Figure 1). The patient did not
respond as well as is expected after an SDH evacuation. A follow-
up CT scan on day 2 revealed a persistent midline-shift, as well
as new occipital infarcts, assumed to be secondary to cerebral
herniation.
The patient improved to a GCS of 9 (E1+M6+V2; E, Eye; M,
Motor response; V, Voice) on day 2. On day 4, the patient deteri-
orated, GCS 6 (E1+M4+V1). A CT scan revealed an increased
midline-shift, so a re-evacuation was performed later the same
day and an intra-cranial pressure (ICP) monitor (Codman®) was
inserted. The dura was thicker than normal and the subdural
mass did not look like a conventional hematoma, so samples were
acquired for further pathological examination. Post-operatively
the patient demonstrated a refractory critically unstable ICP rang-
ing 15–30 mmHg and an increasing midline-shift on CT scan.
Therapeutic management included hyperosmotic fluid, deep seda-
tion with Midazolam, Morphine and Propofol, and hypother-
mia therapy. To facilitate treatment an external ventricular drain
(EVD) was inserted. The S-100B levels were followed twice a day
and showed an unusual peak of 22µg/l (normal range<0.11µg/l)
on day 5 (Figure 1).
Other sources of the extreme S-100B levels, including
encephalitis, new cerebral infarctions, and extra-cerebral sources
such as malignant melanoma, were pursued. Further head CT
scans, including CT-angiography, showed no new findings. An
EEG did not show any epileptic activity, MRI confirmed multi-
ple infarcts, more than previously detected (Figure 3) yet no other
information regarding the dura. A CT scan of thorax and abdomen
showed widespread lung and liver metastases (not shown). Later
day 5, a decompressive left-sided hemicraniectomy was performed
(Figure 1, point E).
While the S-100B declined post-operatively, the patient’s ICP
was still refractory unstable and the midline-shift remained 15–
16 mm (Figure 4). Despite optimized neurosurgical intensive care,
the patient showed steadily increasing ICP so treatment was finally
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FIGURE 1 | Above: Graph showing serum concentration of S-100B (µg/l)
over time (days). Arrows indicating neurosurgical interventions. (A)
Evacuation of subdural mass (NCSP code AAD10). (B) Re-evacuation of
subdural mass and placement of ICP-monitoring device (Codman®; AAD05,
AAA20). (C) Insertion of external ventricular drain (AAF00). (D)
Hemicraniectomy left side (AAK99). Numbers indicating performed
radiological examinations [Computerized Tomography (CT) of the head if not
otherwise stated]. (1) 15 mm midline shift to the right because of left side
subdural mass. Old ischemic lesion in left side internal capsule (Figure 2). (2)
Post-op evacuation, midline shift 12 mm, still compressed sulci. (3) Midline
shift 11 mm, small frontal left-sided hematoma. Diffuse ischemic lesions left
side occipital lobe. (4) Midline shift 15 mm, infarction in posterior cerebral
artery left side and partially on the right side. (5) Post-op evacuation, middle
shift 10 mm, unchanged ischemic lesions. (6) Midline shift 10 mm, better
general conditions regarding intra-cranial mass effect, unchanged ischemic
lesions. (7) CT-angiography: no signs of cerebral artery stenosis, dissection, or
vasospasm. (8) Midline shift 10 mm, unchanged ischemic lesions. (9)
CT-Thorax/Upper abdominal: 4.5 cm wide tumor in the lung, right upper lobe
with growth to the mediastinum. Smaller cancerogenic lumps in the lung
parenchyma. Multiple metastasis to the liver. (10) Magnetic resonance
imaging (MRI): Midline shift 14 mm, compression of the brain stem.
Infarctions in right side thalamus, internal capsule, pons, mesencephalon.
Cortical infarctions left occipital lobe and right occipital lobe. Cerebellar
infarctions (Figure 3). (11) Post-op hemicraniectomy. Thin line of blood
beneath synthetic dura. Twelve millimeters midline shift. Unchanged ischemic
areas. (12) (On day 8) Midline shift 16 mm, epidural hematoma with local
mass effect. Brain stem herniation, compressed basal cisternae (Figure 4).
Below: Graph showing the temporal profile of serum concentration of NSE
(µg/l) over time (days). Two data points are missing due to hemolysis
contaminating the sample.
withdrawn. The patient passed away on day 8 of his hospital stay
due to brain herniation.
The pathologist reported that extensive granulomatous tis-
sue was noted within the hematoma and dura during the re-
evacuation. The histopathological examination showed cells posi-
tive for S-100, Melan A, and HMB45, making metastases of malig-
nant melanoma most probable. An autopsy confirmed malignant
melanoma metastasis within the lungs, pleura, and lymphatic
system. Metastatic tumor growth was also found in the brain
parenchyma, dura, gallbladder, and kidneys.
BACKGROUND
The protein S-100B is an increasingly used biomarker within neu-
rosurgery and neurointensive care. The calcium-binding protein,
which is synthesized and released by cells mainly found in the CNS
(Moore, 1982), is primarily an astrocytic protein but is also located
in other cells of the CNS, such as neurons, oligodendrocytes, and
choroid plexus epithelium (Steiner et al., 2007).
Both serum and CSF S-100B have been proposed to be valu-
able biomarkers of traumatic brain injury (TBI; Herrmann et al.,
1999, 2001). In the early process, S-100B can help estimate the
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FIGURE 2 | Computerized tomography of the head (CT) on admission
showing a left-sided sudural mass and a gross midline-shift of 15mm.
extent of the primary injury (Herrmann et al., 1999; Savola
et al., 2004), monitor potential secondary insults (Raabe et al.,
2004; Bellander et al., 2011) and be an asset in outcome pre-
diction (Herrmann et al., 2001; Savola et al., 2004; Thelin et al.,
submitted).
Increased S-100B levels have also been found in patients suf-
fering from ischemic cerebrovascular insults (Jonsson et al., 2001;
Foerch et al., 2004). Vasospasm and long-term outcome in sub-
arachnoid hemorrhages have been shown to correlate to increased
levels of S-100B (Oertel et al., 2006). CNS infections may alter
S-100B levels such as viral and bacterial meningoencephalitis and
neuroborreliosis (Lins et al., 2005) and herpes simplex encephalitis
(Studahl et al., 2009).
Clinically, S-100B is also the most widely used biomarker in
malignant melanoma patients (Smit et al., 2008). The main use is
monitoring of advance disease, staining of histopathological sam-
ples and to evaluate the efficacy of therapy (Martenson et al., 2001;
Smit et al., 2008; Egberts et al., 2009).
Serum samples of S-100B were obtained on admission to
Karolinska University Hospital and approximately every 12 h
(06:00 and 18:00). All serum samples were arterial and ana-
lyzed using an automatic electro-chemiluminescence immunoas-
say (Elecsys S-100B®; Roche Diagnostics, Penzberg, Germany)
method. The serum levels of S-100B and NSE, and radiological
findings, were acquired using the medical files from the hospital
database system Take Care® (CompuGroup Medical Sweden AB,
FIGURE 3 | Diffusion weighted magnetic resonance imaging (DWI MRI)
of the brain on day 5.The white arrows highlight the ischemic regions in
the left and right occipital lobes.
Farsta, Sweden). The ICP was acquired using ICU-Pilot® (Dipylon
Medical, Solna, Sweden).
DISCUSSION
This case report demonstrates a patient with remarkably high
S-100B levels and complex CNS pathology of unknown origin.
Throughout the NICU stay, frequent serum S-100B levels were
sampled and used as an indicator of a potential underlying CNS
injury and as a guide for management (Figure 1). There are, to our
knowledge, no studies that investigate the relationship between
chronic subdural hematoma and S-100B.
Regarding surgery and levels of S-100B, a study has shown
that EVD insertion does not yield any significant increase of S-
100B compared to base line levels (Woertgen et al., 2004) while
hemicraniectomy has been shown to increase the levels of S-100B
(Korfias et al., 2007). There appears to be a connection between
increasing levels of S-100B in serum and the time of surgery B
(re-evacuation) and C (insertion of EVD; Figure 1). It is diffi-
cult to determine if the first surgical procedure was a source of
S-100B. as no sample was acquired prior to surgery. Nonetheless,
there seem to be no obvious correlation between the hemicraniec-
tomy (Figure 1, point D) and the 22µg/l “peak” of S-100B. Other
sources than the surgical trauma appears to influence the serum
concentration.
S-100B has been shown to have a relatively short half-life, in
studies between 30 and 90 min (Jonsson et al., 2000; Ghanem
et al., 2001); hence, timing of S-100B sampling may be crucial.
Worse outcome has been seen in TBI patients with increasing
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FIGURE 4 | CT on day 11, 4 days post a left-sided hemicraniectomy. An
EVD catheter in situ in the right hemisphere. There is a left-sided epidural
expansive mass adjacent to the duraplasty (artificial membrane) causing a
severe midline-shift.
serum levels of S-100B (Pelinka et al., 2003) but this might be
difficult to translate to the present case since no obvious traumatic
intra-cranial lesions were present.
It is known that cerebral ischemia increases serum levels of S-
100B. The development of several small cerebral infarcts is more
likely to have contributed to the serum S-100B levels than potential
traumatic lesions, in this case. CT-angiography performed during
the period of high levels of S-100B (Figure 1, point 7) did not
find any cerebral vasospasm that could contribute to increased
serum concentrations. On day 2, the patient developed bilateral
PCA infarctions. There is a possibility that there was a progress of
the cerebral infarctions that was not seen prior to the performed
MRI (Figure 3). In this patient cerebral ischemia and chronic SDH
were the only detectable, as found by radiological examinations,
source of S-100B from CNS.
Another factor supporting CNS as a source of S-100B in this
patient is the Neuron Specific Enolase (NSE) levels that fol-
low closely the trend of the S-100B concentration (Figure 1;
R2= 0.602, p< 0.001). NSE, a cytoplasmic glycolytic enzyme of
neurons, generally follows the trend of S-100B after TBI and vas-
cular cerebral injuries (Woertgen et al., 1997). In a study from 2003
there is shown that only raised serum levels of S-100B may indicate
release from non-nervous tissues as a sign of potential multi-
organ dysfunction, while NSE is more CNS specific (Kleine et al.,
2003). Since NSE follows the trend of S-100B, it supports CNS
as the main contributor of serum S-100B. A correlation has been
found between increased ICP and the levels of S-100B and NSE
(Olivecrona et al., 2009), but this did not yield serum concentra-
tions of S-100B in the same magnitude as our patient’s. The ICP
was elevated (above 20 mmHg) on several occasions, especially
during day 5 to day 7.
S-100B has been suggested to be a marker of disturbed blood-
brain barrier (BBB) integrity (Kapural et al., 2002), indicating
that a damaged BBB may leak proteins, such as S-100B from the
CSF into the blood and that this ratio may be used to quantify
the BBB disruption. Other references point out that the serum
levels of S-100B do not correlate to BBB integrity but instead
probably reflect the true cellular damage, as seen in TBI (Bel-
lander et al., 2011). The ratio between CSF-albumin and serum-
albumin is commonly used to quantify BBB integrity (Tibbling
et al., 1977). In this case the CSF levels of S-100B were low (4.2–
13µg/l) compared to what is seen after TBI (1649± 415µg/l,
mean± SEM; Hayakata et al., 2004) and the ratio between CSF-
serum-albumin were 0.001–0.002, clearly below 0.007 (Tibbling
et al., 1977), the limit for disturbed BBB integrity. Hence, no BBB
damage was indicated, making it less likely that the CNS is the
only contributor to the serum concentration of S-100B in the
present case.
Schwann cells, adipose tissue, muscle cells, myocardium, and
melanocytes also contain S-100B (Anderson et al., 2001). S-100B is
the most widely used biomarker in malignant melanoma patients
where it is used to evaluate the efficacy of therapy (Martenson
et al., 2001; Smit et al., 2008; Egberts et al., 2009). In serum
concentrations, stage III malignant melanoma shows mean lev-
els of 0.71µg/l and the highest serum levels are seen in patients
with visceral, bone, and/or brain metastasis (0.6–1.7µg/l; Marten-
son et al., 2001). The present patient had a 3 cm× 2 cm wide
and 0.9 mm thick malignant melanoma (Clarke grade III) on
his shoulder that was radically excised 9 years previously. The
follow-up controls did not show any new skin abnormalities
and the patient was believed to be in remission. A CT scan did
show widespread metastases in the liver and lung (not shown),
confirmed by the clinical autopsy revealing a lymphatic spread
and metastasis to the brain, dura, gallbladder, and kidney with
a histological examination indicating malignant melanoma. The
highest levels of S-100B were seen almost simultaneously as neu-
rosurgical procedures were performed, processes that might have
triggered a surge of S-100B into the serum affecting the total serum
concentration.
Extremely high serum concentrations of S-100B have been
reported preoperatively during cardiac surgery (40µg/l; Anderson
et al., 2001) and within an hour after severe TBI (22µg/l; Thelin et
al., submitted). One person with malignant melanoma showed a
serum level of 126µg/l, which was thought to be due to cell damage
and necrosis of tumor sites (Ghanem et al., 2001), even S-100B lev-
els as high as 221µg/l have been reported in end stage melanoma
patients (Martenson et al., 2001). Due to its short half-life, S-100B
elevations seen in extra-cranial trauma are generally lower when
samples are obtained later (median levels ranging 0.18–0.57µg/l;
Korfias et al., 2006; Stalnacke et al., 2006) than those seen in cere-
bral pathology such as TBI (mean levels ranging 1.7–4.01µg/l;
Herrmann et al., 2001; Savola et al., 2004) and ischemic cerebral
infarcts (mean levels ranging 0.38–2.41µg/l; Jonsson et al., 2001;
Foerch et al., 2004) and extra-cranial S-100B generally do not
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contribute to the total concentration of S-100B if continuously
sampled (Pham et al., 2010).
Our patient was exceptional with a late (day 5), steep increase
(>20µg/l) in serum levels of S-100B. Since S-100B follows NSE,
some degree of CNS specificity is probable even though CSF levels
of the biomarkers were low. There might have been amplifica-
tion of the S-100B concentrations of intra-cranial origin due to
the widespread malignant melanoma, especially from the tumor
located within the dura where surgery might have induced S-100B
release.
CONCLUDING REMARKS
This case report of a gentleman with a chronic SDH, previ-
ous malignant melanoma, and sky-high S-100B levels serves as
a reminder of potential extra-cerebral sources of error when
utilizing S-100B as a biomarker.
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